Completion of Acquisition and TVR

RNS Number : 1937S

Alliance Pharma PLC

21 June 2018

 

                                                                                                                                                                21 June 2018

Alliance Pharma plc 

("Alliance" or the "Group")

Completion of Acquisition and Total Voting Rights

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that following today's admission of 37,362,638 new ordinary shares, it has completed the acquisition of the Nizoral Rights. This follows the announcements made by the Company on 19 June 2018 in relation to the Acquisition and Placing.

The Company now has a total of 514,205,522 ordinary shares in issue. The figure of 514,205,522 ordinary shares should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement of the Company released at 7.00 a.m. BST on 19 June 2018.

For further information:
Alliance Pharma plc	Tel:  [phone]
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Numis Securities Limited	Tel:  [phone]
Nominated Adviser: Michael Meade / Freddie Barnfield / Freddie Naylor-Leyland
Corporate Broking: James Black
Investec Bank plc	Tel:  [phone]
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb / David Herring
Buchanan	Tel:  [phone]
Mark Court / Sophie Wills / Gemma Mostyn-Owen
[e-mail]

Notes to editors

Alliance Pharma plc is an international specialty pharmaceutical company.

Headquartered in Chippenham, UK, Alliance commenced trading in 1998 and has been listed on AIM since 2003. Alliance has a strong track record of acquiring established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. It has sales in more than 100 countries either directly via its affiliates or through its selected network of distributor partners. Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

ACQSESFIFFASEFM